XORTX Q3 Interim Report: Going-Concern Warning, $318,846 Cash, Material Weakness Persists
XRTX sits 24% above its 52-week low of $0.815 on elevated volume (2.1× avg).
Summary
XORTX reported $318,846 of cash at September 30, 2026 against a ~$282,000 monthly burn and repeated its going-concern warning, while disclosing that its material weakness in internal controls remains unremediated.
Key Events · Earnings and Guidance · XRTX
-
Going-Concern Warning Reiterated
Note 1 states conditions indicate a material uncertainty that casts significant doubt about the Company's ability to continue as a going concern.
-
Cash Down to $318,846
Cash fell from $864,514 at December 31, 2025 to $318,846 at September 30, 2026; MD&A puts current cash burn at approximately $282,000 per month excluding IR activities.
-
Nine-Month Loss Widens
Net loss was $2,881,306 ($1.79 per share) versus $2,065,842 ($2.50 per share) a year earlier, with investor relations expense of $1,011,044 in the period.
-
Material Weakness Not Remediated
Management determined DC&P and ICFR were not effective at September 30, 2026 because of a material weakness in the period-end closing process and related review controls; remediation steps are not yet operating effectively.
Analysis · XRTX · Life Sciences
With $318,846 of cash at September 30, 2026 and a burn of roughly $282,000 a month, XORTX is measuring its runway in weeks, not quarters — and management states plainly that conditions raise significant doubt about the company's ability to continue as a going concern. The nine-month loss widened to $2,881,306 from $2,065,842 a year earlier, driven largely by a $1,011,044 investor relations charge tied to the IR Agency LLC agreement. Gross proceeds from the May 2026 offering were $4,999,999, but issuance costs consumed $961,720, and most of the securities sold were pre-funded warrants at $0.0001 — 2,996,147 of them still outstanding at period end, plus 344,000 exercised after the quarter for $34. On top of that, management says the previously identified material weakness in the period-end closing process is not yet operating effectively, so disclosure controls and ICFR were again deemed not effective. New financing is needed before the XRx-026 IND and the XRX-OXY-102 study can proceed.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XRTX was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $0.82 to $3.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.